Literature DB >> 20483149

Escherichia coli 83972 bacteriuria protects against recurrent lower urinary tract infections in patients with incomplete bladder emptying.

Fredrik Sundén1, Lars Håkansson, Eva Ljunggren, Björn Wullt.   

Abstract

PURPOSE: We determined if the deliberate establishment of asymptomatic bacteriuria with Escherichia coli 83972 in patients with incomplete bladder emptying and recurrent urinary tract infection protects against recurrence.
MATERIALS AND METHODS: In phase 1 of the study the patients were randomized to blinded inoculations with E. coli 83972 or saline. Crossover occurred after monitoring for 12 months or after a urinary tract infection. The outcome was the time to the first urinary tract infection in patients with and without E. coli 83972 bacteriuria. In phase 2 patients were subjected to additional blinded inoculations to extend periods with and without E. coli 83972 bacteriuria. The outcome was the number of urinary tract infections during 12 months with and 12 months without E. coli 83972 bacteriuria.
RESULTS: A total of 20 patients completed the study. In phase 1 the time to the first urinary tract infection was longer with than without E. coli 83972 bacteriuria (median 11.3 vs 5.7 months, sign test p = 0.0129). Phase 2 was analyzed after patients had spent a total of 202 months with and 168 months without E. coli 83972 bacteriuria. There were fewer reported urinary tract infection episodes with vs without E. coli 83972 bacteriuria (13 vs 35 episodes, paired t test p = 0.009, CI 0.31-1.89). There was no febrile urinary tract infection episode in either of the study arms and no significant side effects of intravesical bacterial inoculation were reported.
CONCLUSIONS: Deliberately induced E. coli 83972 bacteriuria protected patients with incomplete bladder emptying who are prone to urinary tract infection from recurrent urinary tract infection as demonstrated by the delay in time to urinary tract infection and the decrease in number of urinary tract infection episodes. Copyright (c) 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20483149     DOI: 10.1016/j.juro.2010.03.024

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  60 in total

Review 1.  Asymptomatic bacteriuria: when the treatment is worse than the disease.

Authors:  Barbara W Trautner
Journal:  Nat Rev Urol       Date:  2011-12-06       Impact factor: 14.432

Review 2.  Genetics of innate immunity and UTI susceptibility.

Authors:  Bryndís Ragnarsdóttir; Nataliya Lutay; Jenny Grönberg-Hernandez; Bela Köves; Catharina Svanborg
Journal:  Nat Rev Urol       Date:  2011-07-12       Impact factor: 14.432

3.  Decreased microbiota diversity associated with urinary tract infection in a trial of bacterial interference.

Authors:  Deborah Horwitz; Tyler McCue; Abigail C Mapes; Nadim J Ajami; Joseph F Petrosino; Robert F Ramig; Barbara W Trautner
Journal:  J Infect       Date:  2015-06-03       Impact factor: 6.072

Review 4.  [Primary and secondary prevention of urinary tract infections].

Authors:  F M E Wagenlehner; W Vahlensieck; H W Bauer; W Weidner; K G Naber; H J Piechota
Journal:  Urologe A       Date:  2011-10       Impact factor: 0.639

Review 5.  Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies.

Authors:  Roger D Klein; Scott J Hultgren
Journal:  Nat Rev Microbiol       Date:  2020-02-18       Impact factor: 60.633

6.  The impact of microbiome in urological diseases: a systematic review.

Authors:  Joseph K M Li; Peter K F Chiu; Chi-Fai Ng
Journal:  Int Urol Nephrol       Date:  2019-07-12       Impact factor: 2.370

7.  Active bacterial modification of the host environment through RNA polymerase II inhibition.

Authors:  Inès Ambite; Nina A Filenko; Elisabed Zaldastanishvili; Daniel Sc Butler; Thi Hien Tran; Arunima Chaudhuri; Parisa Esmaeili; Shahram Ahmadi; Sanchari Paul; Björn Wullt; Johannes Putze; Swaine L Chen; Ulrich Dobrindt; Catharina Svanborg
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

Review 8.  Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics.

Authors:  David Lebeaux; Jean-Marc Ghigo; Christophe Beloin
Journal:  Microbiol Mol Biol Rev       Date:  2014-09       Impact factor: 11.056

9.  Systematic review: bacterial colonisation of conduits and neobladders-when to test, watch, and treat.

Authors:  Liang G Qu; Ahmed Adam; Weranja Ranasinghe; Nathan Lawrentschuk
Journal:  World J Urol       Date:  2019-09-27       Impact factor: 4.226

10.  Direct injection of functional single-domain antibodies from E. coli into human cells.

Authors:  Ana Blanco-Toribio; Serge Muyldermans; Gad Frankel; Luis Ángel Fernández
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.